Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Prostatic Cancer, Castration-Resistant
Interventions: Darolutamide (Nubeqa, BAY1841788), Enzalutamide; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Portland, Maine • Voorhees Township, New Jersey • The Bronx, New York + 4 more

Conditions: HIV Infections
Interventions: Rosiglitazone maleate, Atazanavir Sulphate, Atazanavir Sulphate + Rosiglitazone maleate, Atazanavir Sulphate + Ritonavir, Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Ovarian Neoplasm
Interventions: liposomal doxorubicin; Drug
Lead sponsor: Southeastern Gynecologic Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions: trastuzumab, aromatase inhibition therapy, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, metabolic assessment, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, positron emission tomography, fludeoxyglucose F 18; Biological · Drug · Other + 2 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Onychomycosis
Interventions: Albaconozole, Placebo; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Neonatal Abstinence Syndrome
Interventions: Clonidine, Morphine; Drug
Lead sponsor: Henrietta Bada; Other
Eligibility: 12 Hours to 7 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy Volunteers
Interventions: Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC); Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Trigeminal Neuropathy
Interventions: Erenumab-Aooe, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: galantamine; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atherosclerosis
Interventions: Darapladib, Diltiazem; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: Deucravacitinib, Famotidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Type 2
Interventions: Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: Foods with beta-glucan from oats and barley; Other
Lead sponsor: General Mills; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Smoking, Tobacco Use, Tobacco Smoking
Interventions: Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B, Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B, Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B, Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B, Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A; Other
Lead sponsor: British American Tobacco (Investments) Limited; Industry
Eligibility: 26 Years to 55 Years
Enrollment: 806 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 18
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 14 more

Conditions: SARS-CoV-2 Infection
Interventions: PF-07817883, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 53
States / cities: Cullman, Alabama • Phoenix, Arizona • Surprise, Arizona + 45 more

Conditions: Depression
Interventions: Chiropractic Applied Clinical Neuroscience; Procedure
Lead sponsor: Life University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Pain
Interventions: Preservative Free Lidocaine, Saline; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 7 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Dextromethorphan, Healthy Adult Volunteers
Interventions: Isavuconazole, dextromethorphan; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Placebo, Methylphenidate, Nicotine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: TAK-906, Esomeprazole; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Performance Enhancing Product Use
Interventions: Suvorexant 10 mg, Zolpidem, Placebos; Drug
Lead sponsor: Walter Reed Army Institute of Research (WRAIR); Federal
Eligibility: 18 Years to 39 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Chemo Fog
Interventions: Ashwagandha, Placebo; Drug
Lead sponsor: Sutter Health; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Volunteers
Interventions: Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mental Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

DOXIL for Consolidation Therapy in Ovarian Cancer.

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

Galantamine for Cognition in People With Schizophrenia

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

Beta-glucan, Product Claims and Satiety

BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

Applied Clinical Neuroscience Care for Self-reported Symptoms of Depression and Cerebellar Function in Adults

The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast:

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects

Effects of Commonly Used Medications on Mood and Choice

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

Ashwagandha for Cognitive Dysfunction

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

Neuropsychiatric Effects of Interferon-Alpha and Ribavirin